

Supplemental Material to:

Adverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents

A Norwegian Nationwide Register-Based Study

Vilde Bergstad Larsen¹, Nina Gunnes^{2,3}, Jon Michael Gran⁴, Jesper Dahl⁵, Håkon Bøås⁵, Sara Viksmoen Watile⁵, Jacob Dag Berild⁵, Margrethe Greve-Isdahl⁵, Ketil Størdal⁶, Hanne Løvdal Gulseth², Øystein Karlstad², Paz Lopez-Doriga Ruiz^{2,7}, German Tapia²

¹Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway

²Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway

³Norwegian Research Centre for Women's Health, Oslo University Hospital, Oslo, Norway

⁴Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway

⁵Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway

⁶Department of Pediatric Research, Institute of Clinical Medicine, University of Oslo, and Oslo University Hospital, Oslo, Norway

⁷Institute of Community Health and Global Medicine, University of Oslo, Oslo, Norway

Corresponding author: German Tapia, Norwegian Institute of Public Health, Marcus Thranes gate 6, 0473 Oslo, Norway; german.tapia@fhi.no

Contents

Supplementary Materials.....	3
Data Sources in Beredt C19	3
National Population Register	3
Norwegian Surveillance System for Communicable Diseases	3
Norwegian Immunisation Registry.....	3
Norwegian Registry of Primary Health Care	3
Norwegian Patient Registry	3
Norwegian Cause of Death Registry	3
<i>Supplementary Table 1</i>	5
<i>Supplementary Table 2</i>	8
<i>Supplementary Table 3</i>	11
<i>Supplementary Table 4:</i>	14
<i>Supplementary Table 5:</i>	17

Supplementary Materials

This section includes additional information about the current study.

Data Sources in Beredt C19

Beredt C19 was established in April 2020 by the Norwegian Institute of Public Health to monitor infections, vaccinations, and use of health services in Norway during the COVID-19 pandemic (<https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/>). The register consists of historical and real-time data from various nationwide electronic health registers and administrative databases to which all reporting is mandatory, thereby covering the entire population in Norway. Data sources in Beredt C19 relevant for the current study are described below.

National Population Register

The National Population Register (<https://www.skatteetaten.no/en/person/national-registry/>) provided information on date and place of birth, sex, date of immigration, county of residence, date of emigration, date of death, and residential status (resident, emigrated, or deceased). The register is updated weekly in Beredt C19.

Norwegian Surveillance System for Communicable Diseases

Information on laboratory-confirmed SARS-CoV-2 infection dates was provided by the Norwegian Surveillance System for Communicable Diseases (MSIS), which is run by the Norwegian Institute of Public Health. All laboratories are legally required to report date of testing and test results to the MSIS. The register is updated daily in Beredt C19.

Norwegian Immunisation Registry

The Norwegian Immunisation Registry (SYSVAK) provided information on SARS-CoV-2 vaccination dates and vaccine types. SYSVAK is run by the Norwegian Institute of Health and updated daily in Beredt C19.

Norwegian Registry of Primary Health Care

The Norwegian Registry of Primary Health Care is based on government reimbursement claims from the primary health services in Norway, including publicly funded general practitioners and primary care emergency clinics. Diagnoses are coded using the International Classification of Primary Care, Second Edition (ICPC-2). The register is updated daily in Beredt C19. In the current study, it provided information on date of diagnosis of herpes zoster (ICPC-2 code S70).

Norwegian Patient Registry

The Norwegian Patient Registry (NPR) collects data from the specialist health services in Norway, which includes all government-owned hospitals and outpatient clinics. Diagnoses are coded using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Reporting to the NPR forms the basis for government reimbursements to the specialist health services in Norway. Together with the Norwegian Registry of Primary Health Care, the NPR covers all government-funded health care in Norway. The register is updated daily in Beredt C19. It provided information on dates of all hospital admissions/discharges and outpatient visits and the corresponding diagnoses.

Norwegian Cause of Death Registry

Information on county of residence for deceased subjects was retrieved from the Norwegian Cause of Death Registry, as home address is deleted from the National Population Register upon death. We also used the Norwegian Cause of Death Registry to ascertain whether any subjects were registered

with vaccine-associated death (ICD-10 code U12.9). The register is run by the Norwegian Institute of Public Health and updated weekly in Beredt C19.

Supplementary Table 1: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 477,097 adolescents in Norway aged 12–19 years at the end of 2021 and unvaccinated against SARS-CoV-2 and previously uninfected with SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination¹ of their age group until the outcome in question, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, SARS-CoV-2 infection, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by “< 5”. As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of subjects	Number of events	Incidence rate ²	Crude analysis			Adjusted analysis ³		
						IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	<i>Overall</i>	472,625	802	217.77						
		Unvaccinated (ref.)	471,868	184	184.88	1			1		
		Vaccinated with 1 st dose, inside risk window	388,948	34	229.38	1.24	0.86–1.79	0.248	1.33	0.90–1.96	0.147
		Vaccinated with 1 st dose, outside risk window	384,298	300	229.31	1.24	1.03–1.49	0.021	1.56	1.25–1.94	0.000
		Vaccinated with 2 nd dose, inside risk window	213,406	20	246.64	1.33	0.84–2.12	0.221	1.42	0.87–2.30	0.159
		Vaccinated with 2 nd dose, outside risk window	210,127	264	229.58	1.24	1.03–1.50	0.024	1.45	1.10–1.90	0.008
Anaphylactic reaction	2 days	<i>Overall</i>	476,333	41	11.04						
		Unvaccinated (ref.)	475,564	9	8.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,153	< 5	46.58	5.19	0.66–40.98	0.118	6.84	0.81–57.81	0.077
		Vaccinated with 1 st dose, outside risk window	391,666	19	13.13	1.46	0.66–3.23	0.347	2.75	1.00–7.56	0.049
		Vaccinated with 2 nd dose, inside risk window	215,309	< 5	84.86	9.46	1.20–74.65	0.033	11.02	1.26–96.68	0.030
		Vaccinated with 2 nd dose, outside risk window	214,849	11	8.94	1.00	0.41–2.40	0.993	0.88	0.26–2.95	0.830
Arrhythmia	28 days	<i>Overall</i>	475,961	90	24.25						
		Unvaccinated (ref.)	475,194	26	25.94	1			1		
		Vaccinated with 1 st dose, inside risk window	391,814	< 5	10.11	0.39	0.12–1.29	0.122	0.38	0.11–1.31	0.126
		Vaccinated with 1 st dose, outside risk window	374,429	24	20.49	0.79	0.45–1.38	0.405	1.12	0.58–2.16	0.726
		Vaccinated with 2 nd dose, inside risk window	215,069	< 5	6.15	0.24	0.03–1.75	0.158	0.20	0.03–1.56	0.126
		Vaccinated with 2 nd dose, outside risk window	210,483	36	33.37	1.29	0.78–2.13	0.328	1.34	0.64–2.82	0.438
Arthropathy	42 days	<i>Overall</i>	476,515	0	0.00						
		Unvaccinated (ref.)	475,746	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	392,319	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	336,587	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	215,425	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,863	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	<i>Overall</i>	476,409	22	5.92						
		Unvaccinated (ref.)	475,640	8	7.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,224	< 5	10.10	1.27	0.34–4.77	0.727	1.26	0.28–5.58	0.764
		Vaccinated with 1 st dose, outside risk window	374,812	7	5.97	0.75	0.27–2.07	0.577	0.88	0.26–2.98	0.838
		Vaccinated with 2 nd dose, inside risk window	215,353	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	210,758	< 5	3.70	0.46	0.14–1.54	0.210	0.27	0.06–1.28	0.100
Death	28 days	<i>Overall</i>	476,515	90	24.22						
		Unvaccinated (ref.)	475,746	36	35.87	1			1		
		Vaccinated with 1 st dose, inside risk window	392,319	7	23.56	0.66	0.29–1.48	0.309	0.71	0.29–1.69	0.433
		Vaccinated with 1 st dose, outside risk window	374,903	18	15.35	0.43	0.24–0.75	0.003	0.59	0.31–1.13	0.110
		Vaccinated with 2 nd dose, inside risk window	215,425	5	30.68	0.86	0.34–2.18	0.743	0.69	0.26–1.87	0.471
		Vaccinated with 2 nd dose, outside risk window	210,830	24	22.21	0.62	0.37–1.04	0.069	0.40	0.20–0.78	0.007
Encephalomyelitis and meningitis	28 days	<i>Overall</i>	476,453	7	1.88						
		Unvaccinated (ref.)	475,684	< 5	1.00	1			1		
		Vaccinated with 1 st dose, inside risk window	392,267	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	374,854	< 5	1.71	1.71	0.16–18.88	0.661	1.18	0.10–13.79	0.895
		Vaccinated with 2 nd dose, inside risk window	215,394	< 5	6.14	6.16	0.39–98.45	0.199	5.98	0.28–126.35	0.251
		Vaccinated with 2 nd dose, outside risk window	210,799	< 5	2.78	2.79	0.29–26.78	0.375	1.69	0.11–26.81	0.709
Epilepsy and convulsions	28 days	<i>Overall</i>	471,600	454	123.56						

		Unvaccinated (ref.)	470,838	107	107.85	1			1		
		Vaccinated with 1 st dose, inside risk window	388,243	29	98.63	0.91	0.61–1.38	0.670	1.07	0.69–1.67	0.749
		Vaccinated with 1 st dose, outside risk window	370,996	157	135.46	1.26	0.98–1.61	0.069	1.21	0.91–1.61	0.187
		Vaccinated with 2 nd dose, inside risk window	213,099	28	173.71	1.61	1.06–2.44	0.025	1.65	1.05–2.59	0.028
		Vaccinated with 2 nd dose, outside risk window	208,521	133	124.53	1.15	0.90–1.49	0.268	1.01	0.71–1.44	0.944
Facial nerve palsy	28 days	<i>Overall</i>	476,148	57	15.35						
		Unvaccinated (ref.)	475,379	19	18.95	1			1		
		Vaccinated with 1 st dose, inside risk window	392,016	< 5	13.47	0.71	0.24–2.09	0.535	0.65	0.21–2.02	0.454
		Vaccinated with 1 st dose, outside risk window	374,613	10	8.54	0.45	0.21–0.97	0.041	0.47	0.20–1.11	0.085
		Vaccinated with 2 nd dose, inside risk window	215,248	< 5	12.28	0.65	0.15–2.78	0.560	0.49	0.11–2.26	0.359
		Vaccinated with 2 nd dose, outside risk window	210,657	22	20.38	1.08	0.58–1.99	0.816	1.02	0.41–2.53	0.964
Guillain-Barré syndrome	42 days	<i>Overall</i>	476,503	< 5	0.81						
		Unvaccinated (ref.)	475,734	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	392,307	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	336,577	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	215,416	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,855	< 5	3.00	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	<i>Overall</i>	476,444	7	1.88						
		Unvaccinated (ref.)	475,675	< 5	1.00	1			1		
		Vaccinated with 1 st dose, inside risk window	392,263	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	336,538	5	4.84	4.85	0.57–41.52	0.149	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	215,397	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,835	< 5	1.00	1.00	0.06–16.04	0.998	ND	ND	ND
Herpes zoster	28 days	<i>Overall</i>	476,297	47	12.65						
		Unvaccinated (ref.)	475,528	9	8.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,127	< 5	6.73	0.75	0.16–3.47	0.714	1.00	0.20–5.09	0.997
		Vaccinated with 1 st dose, outside risk window	374,721	15	12.80	1.43	0.62–3.26	0.399	1.30	0.49–3.42	0.598
		Vaccinated with 2 nd dose, inside risk window	215,299	< 5	6.14	0.68	0.09–5.40	0.719	0.82	0.10–6.85	0.853
		Vaccinated with 2 nd dose, outside risk window	210,710	20	18.52	2.06	0.94–4.53	0.071	1.86	0.62–5.56	0.265
Idiopathic thrombocytopenic purpura	28 days	<i>Overall</i>	476,398	18	4.84						
		Unvaccinated (ref.)	475,629	5	4.98	1			1		
		Vaccinated with 1 st dose, inside risk window	392,227	< 5	6.73	1.35	0.26–6.96	0.719	0.98	0.18–5.44	0.983
		Vaccinated with 1 st dose, outside risk window	374,817	5	4.27	0.86	0.25–2.96	0.806	1.28	0.29–5.71	0.748
		Vaccinated with 2 nd dose, inside risk window	215,372	< 5	6.14	1.23	0.14–10.54	0.849	1.16	0.11–11.87	0.901
		Vaccinated with 2 nd dose, outside risk window	210,779	5	4.63	0.93	0.27–3.21	0.907	2.18	0.37–12.99	0.391
Lymphadenopathy	14 days	<i>Overall</i>	474,345	438	118.44						
		Unvaccinated (ref.)	473,581	97	97.10	1			1		
		Vaccinated with 1 st dose, inside risk window	390,457	15	100.80	1.04	0.60–1.79	0.893	1.23	0.70–2.18	0.474
		Vaccinated with 1 st dose, outside risk window	385,807	157	119.52	1.23	0.96–1.59	0.108	1.29	0.96–1.73	0.094
		Vaccinated with 2 nd dose, inside risk window	214,303	20	245.61	2.53	1.56–4.09	0.000	2.73	1.63–4.58	0.000
		Vaccinated with 2 nd dose, outside risk window	211,014	149	128.98	1.33	1.03–1.72	0.030	1.40	0.98–2.01	0.068
Multisystem inflammatory syndrome in children	42 days	<i>Overall</i>	476,500	6	1.61						
		Unvaccinated (ref.)	475,731	< 5	1.00	1			1		
		Vaccinated with 1 st dose, inside risk window	392,305	< 5	2.30	2.30	0.14–36.83	0.555	1.61	0.09–28.39	0.744
		Vaccinated with 1 st dose, outside risk window	336,576	< 5	1.93	1.94	0.18–21.41	0.588	3.26	0.11–93.03	0.490
		Vaccinated with 2 nd dose, inside risk window	215,420	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,858	< 5	2.00	2.01	0.18–22.13	0.570	3.73	0.08–169.70	0.499
Myocarditis and pericarditis	28 days	<i>Overall</i>	476,463	< 53	13.73						
		Unvaccinated (ref.)	475,694	9	8.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,268	< 5	10.10	1.13	0.30–4.16	0.859	1.57	0.35–7.04	0.557
		Vaccinated with 1 st dose, outside risk window	374,855	13	11.09	1.24	0.53–2.89	0.625	4.84	1.42–16.47	0.012

		Vaccinated with 2 nd dose, inside risk window	215,375	11	67.52	7.53	3.12–18.17	0.000	9.19	2.69–31.45	0.000
		Vaccinated with 2 nd dose, outside risk window	210,769	15	13.89	1.55	0.68–3.54	0.300	3.16	0.79–12.64	0.104
Venous thromboembolic events	28 days	<i>Overall</i>	476,415	< 54	14.00						
		Unvaccinated (ref.)	475,646	9	8.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,221	5	16.83	1.88	0.63–5.60	0.259	2.40	0.67–8.62	0.180
		Vaccinated with 1 st dose, outside risk window	374,811	13	11.09	1.24	0.53–2.89	0.625	2.67	0.85–8.41	0.094
		Vaccinated with 2 nd dose, inside risk window	215,335	< 5	18.42	2.05	0.56–7.58	0.281	2.17	0.48–9.73	0.313
		Vaccinated with 2 nd dose, outside risk window	210,737	22	20.37	2.27	1.05–4.93	0.038	2.53	0.72–8.85	0.147

Abbreviations: CI – confidence interval; IRR – incidence rate ratio; mRNA – messenger RNA; ND – not determined

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), attained age by the end of 2021 (12–15 years, 16–17 years, or 18–19 years), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 2: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 253,669 adolescents in Norway aged 12–15 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination¹ of their age group until the outcome in question, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by “< 5”. As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of subjects	Number of events	Incidence rate ²	Crude analysis			Adjusted analysis ³		
						IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	<i>Overall</i>	251,681	< 539	200.50						
		Unvaccinated (ref.)	250,982	123	151.17	1			1		
		Vaccinated with 1 st dose, inside risk window	188,097	18	249.69	1.65	1.01–2.71	0.047	1.91	1.12–3.27	0.017
		Vaccinated with 1 st dose, outside risk window	188,054	367	225.83	1.49	1.22–1.83	0.000	1.40	1.14–1.74	0.002
		Vaccinated with 2 nd dose, inside risk window	28,920	< 5	180.78	1.20	0.30–4.84	0.802	1.13	0.28–4.61	0.860
		Vaccinated with 2 nd dose, outside risk window	28,813	26	171.73	1.14	0.74–1.73	0.555	1.06	0.68–1.63	0.806
Anaphylactic reaction	2 days	<i>Overall</i>	253,579	21	7.79						
		Unvaccinated (ref.)	252,869	5	6.10	1			1		
		Vaccinated with 1 st dose, inside risk window	189,544	< 5	96.35	15.81	1.85–135.31	0.012	16.19	1.29–202.98	0.031
		Vaccinated with 1 st dose, outside risk window	189,535	13	7.64	1.25	0.45–3.52	0.668	1.16	0.40–3.38	0.779
		Vaccinated with 2 nd dose, inside risk window	29,154	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	29,124	< 5	12.32	2.02	0.39–10.42	0.401	1.35	0.25–7.30	0.731
Arrhythmia	28 days	<i>Overall</i>	253,474	49	18.18						
		Unvaccinated (ref.)	252,765	14	17.08	1			1		
		Vaccinated with 1 st dose, inside risk window	189,459	< 5	6.89	0.40	0.05–3.07	0.380	0.31	0.04–2.40	0.261
		Vaccinated with 1 st dose, outside risk window	189,193	29	18.52	1.08	0.57–2.05	0.803	1.26	0.62–2.55	0.528
		Vaccinated with 2 nd dose, inside risk window	29,146	< 5	44.94	2.63	0.35–20.01	0.350	3.75	0.47–30.02	0.213
		Vaccinated with 2 nd dose, outside risk window	28,909	< 5	28.25	1.65	0.54–5.03	0.374	1.89	0.57–6.22	0.294
Arthropathy	42 days	<i>Overall</i>	253,666	0	0.00						
		Unvaccinated (ref.)	252,956	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	189,617	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,147	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	29,176	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,843	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	<i>Overall</i>	253,630	< 15	5.19						
		Unvaccinated (ref.)	252,920	< 5	4.88	1			1		
		Vaccinated with 1 st dose, inside risk window	189,585	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,320	10	6.38	1.31	0.41–4.17	0.649	1.28	0.35–4.70	0.706
		Vaccinated with 2 nd dose, inside risk window	29,168	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,932	0	0.00	ND	ND	ND	ND	ND	ND
Death	28 days	<i>Overall</i>	253,666	32	11.86						
		Unvaccinated (ref.)	252,956	18	21.94	1			1		
		Vaccinated with 1 st dose, inside risk window	189,617	< 5	6.88	0.31	0.04–2.35	0.259	0.43	0.05–3.46	0.426
		Vaccinated with 1 st dose, outside risk window	189,352	12	7.66	0.35	0.17–0.72	0.005	0.31	0.15–0.66	0.002
		Vaccinated with 2 nd dose, inside risk window	29,176	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,940	< 5	7.05	0.32	0.04–2.41	0.269	0.22	0.03–1.66	0.140
Encephalomyelitis and meningitis	28 days	<i>Overall</i>	253,632	5	1.85						
		Unvaccinated (ref.)	252,922	< 5	2.44	1			1		
		Vaccinated with 1 st dose, inside risk window	189,592	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,327	< 5	1.91	0.78	0.13–4.70	0.791	0.71	0.12–4.27	0.708
		Vaccinated with 2 nd dose, inside risk window	29,169	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,933	0	0.00	ND	ND	ND	ND	ND	ND
Epilepsy and convulsions	28 days	<i>Overall</i>	251,005	< 301	111.34						

		Unvaccinated (ref.)	250,300	92	113.45	1			1		
		Vaccinated with 1 st dose, inside risk window	187,667	18	125.16	1.10	0.67–1.83	0.703	1.28	0.75–2.18	0.368
		Vaccinated with 1 st dose, outside risk window	187,388	170	109.62	0.97	0.75–1.25	0.790	0.91	0.70–1.18	0.467
		Vaccinated with 2 nd dose, inside risk window	28,818	< 5	45.45	0.40	0.06–2.87	0.363	0.33	0.05–2.37	0.269
		Vaccinated with 2 nd dose, outside risk window	28,583	16	114.43	1.01	0.59–1.72	0.975	0.92	0.53–1.58	0.751
Facial nerve palsy	28 days	<i>Overall</i>	253,469	37	13.73						
		Unvaccinated (ref.)	252,759	18	21.96	1			1		
		Vaccinated with 1 st dose, inside risk window	189,480	< 5	13.77	0.63	0.15–2.70	0.532	0.76	0.16–3.57	0.731
		Vaccinated with 1 st dose, outside risk window	189,213	14	8.94	0.41	0.20–0.82	0.012	0.38	0.18–0.78	0.008
		Vaccinated with 2 nd dose, inside risk window	29,144	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,908	< 5	21.19	0.96	0.28–3.28	0.954	0.73	0.21–2.59	0.626
Guillain-Barré syndrome	42 days	<i>Overall</i>	253,663	< 5	1.11						
		Unvaccinated (ref.)	252,953	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	189,614	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,144	< 5	1.34	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	29,175	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,842	< 5	7.65	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	<i>Overall</i>	253,622	< 10	2.22						
		Unvaccinated (ref.)	252,912	< 5	1.22	1			1		
		Vaccinated with 1 st dose, inside risk window	189,586	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,116	5	3.35	2.74	0.32–23.49	0.357	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	29,173	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,840	0	0.00	ND	ND	ND	ND	ND	ND
Herpes zoster	28 days	<i>Overall</i>	253,556	< 44	14.84						
		Unvaccinated (ref.)	252,846	10	12.19	1			1		
		Vaccinated with 1 st dose, inside risk window	189,529	< 5	6.88	0.56	0.07–4.41	0.586	1.23	0.13–11.20	0.857
		Vaccinated with 1 st dose, outside risk window	189,263	24	15.32	1.26	0.60–2.63	0.544	1.01	0.47–2.16	0.976
		Vaccinated with 2 nd dose, inside risk window	29,146	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,911	5	35.32	2.90	0.99–8.48	0.052	1.57	0.52–4.75	0.427
Idiopathic thrombocytopenic purpura	28 days	<i>Overall</i>	253,601	13	4.82						
		Unvaccinated (ref.)	252,891	< 5	3.66	1			1		
		Vaccinated with 1 st dose, inside risk window	189,572	< 5	13.77	3.76	0.63–22.51	0.147	3.06	0.42–22.09	0.267
		Vaccinated with 1 st dose, outside risk window	189,305	8	5.11	1.39	0.37–5.26	0.623	1.96	0.40–9.74	0.408
		Vaccinated with 2 nd dose, inside risk window	29,168	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,933	0	0.00	ND	ND	ND	ND	ND	ND
Lymphadenopathy	14 days	<i>Overall</i>	252,508	< 293	108.07						
		Unvaccinated (ref.)	251,803	74	90.65	1			1		
		Vaccinated with 1 st dose, inside risk window	188,737	6	82.95	0.92	0.40–2.10	0.834	1.12	0.47–2.69	0.798
		Vaccinated with 1 st dose, outside risk window	188,706	185	113.37	1.25	0.96–1.64	0.104	1.15	0.87–1.52	0.338
		Vaccinated with 2 nd dose, inside risk window	28,993	< 5	180.34	1.99	0.49–8.10	0.337	1.65	0.40–6.78	0.487
		Vaccinated with 2 nd dose, outside risk window	28,885	23	151.57	1.67	1.05–2.67	0.031	1.53	0.94–2.48	0.087
Multisystem inflammatory syndrome in children	42 days	<i>Overall</i>	253,650	12	4.45						
		Unvaccinated (ref.)	252,940	5	6.09	1			1		
		Vaccinated with 1 st dose, inside risk window	189,607	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,137	7	4.68	0.77	0.24–2.42	0.652	1.16	0.29–4.55	0.834
		Vaccinated with 2 nd dose, inside risk window	29,176	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,843	0	0.00	ND	ND	ND	ND	ND	ND
Myocarditis and pericarditis	28 days	<i>Overall</i>	253,659	10	3.71						
		Unvaccinated (ref.)	252,949	< 5	3.66	1			1		
		Vaccinated with 1 st dose, inside risk window	189,611	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,346	5	3.19	0.87	0.21–3.65	0.852	1.30	0.25–6.75	0.757

		Vaccinated with 2 nd dose, inside risk window	29,174	< 5	44.89	12.27	1.28–117.98	0.030	37.07	2.79–492.94	0.006
		Vaccinated with 2 nd dose, outside risk window	28,937	< 5	7.06	1.93	0.20–18.54	0.569	4.12	0.31–54.93	0.285
Venous thromboembolic events	28 days	<i>Overall</i>	253,650	16	5.93						
		Unvaccinated (ref.)	252,940	< 5	2.44	1			1		
		Vaccinated with 1 st dose, inside risk window	189,604	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,339	13	8.29	3.41	0.77–15.10	0.107	6.03	0.78–46.37	0.084
		Vaccinated with 2 nd dose, inside risk window	29,169	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,933	< 5	7.06	2.90	0.26–31.96	0.385	8.94	0.52–154.10	0.131

Abbreviations: CI – confidence interval; IRR – incidence rate ratio; mRNA – messenger RNA; ND – not determined

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 3: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 121,179 adolescents in Norway aged 16–17 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination¹ of their age group until the outcome in question, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by “< 5”. As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of subjects	Number of events	Incidence rate ²	Crude analysis			Adjusted analysis ³		
						IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	<i>Overall</i>	120,117	300	227.97						
		Unvaccinated (ref.)	120,049	26	122.19	1			1		
		Vaccinated with 1 st dose, inside risk window	106,881	7	170.88	1.40	0.61–3.22	0.431	1.07	0.45–2.56	0.878
		Vaccinated with 1 st dose, outside risk window	106,863	81	261.83	2.14	1.38–3.33	0.001	2.38	1.50–3.77	0.000
		Vaccinated with 2 nd dose, inside risk window	91,662	10	284.68	2.33	1.12–4.83	0.023	2.81	1.30–6.09	0.009
		Vaccinated with 2 nd dose, outside risk window	91,618	176	245.22	2.01	1.33–3.03	0.001	2.19	1.38–3.48	0.001
Anaphylactic reaction	2 days	<i>Overall</i>	121,129	< 17	10.54						
		Unvaccinated (ref.)	121,060	< 5	9.32	1			1		
		Vaccinated with 1 st dose, inside risk window	107,798	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	107,796	5	14.37	1.54	0.30–7.96	0.604	1.79	0.34–9.43	0.495
		Vaccinated with 2 nd dose, inside risk window	92,475	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,474	7	9.27	0.99	0.21–4.79	0.995	0.82	0.15–4.55	0.823
Arrhythmia	28 days	<i>Overall</i>	121,024	< 36	24.11						
		Unvaccinated (ref.)	120,956	6	27.98	1			1		
		Vaccinated with 1 st dose, inside risk window	107,700	< 5	12.13	0.43	0.05–3.60	0.438	0.33	0.04–2.98	0.324
		Vaccinated with 1 st dose, outside risk window	106,724	6	22.15	0.79	0.26–2.45	0.685	1.23	0.32–4.66	0.763
		Vaccinated with 2 nd dose, inside risk window	92,396	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,318	19	27.59	0.99	0.39–2.47	0.976	1.63	0.47–5.64	0.437
Arthropathy	42 days	<i>Overall</i>	121,179	0	0.00						
		Unvaccinated (ref.)	121,110	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	107,846	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	105,676	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	92,518	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,393	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	<i>Overall</i>	121,144	11	8.28						
		Unvaccinated (ref.)	121,075	< 5	9.32	1			1		
		Vaccinated with 1 st dose, inside risk window	107,818	< 5	36.34	3.90	0.65–23.33	0.136	5.52	0.71–42.97	0.102
		Vaccinated with 1 st dose, outside risk window	106,839	< 5	7.37	0.79	0.11–5.61	0.815	0.61	0.08–4.51	0.630
		Vaccinated with 2 nd dose, inside risk window	92,488	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,410	< 5	5.80	0.62	0.11–3.40	0.584	0.56	0.09–3.56	0.542
Death	28 days	<i>Overall</i>	121,179	< 31	21.82						
		Unvaccinated (ref.)	121,110	5	23.29	1			1		
		Vaccinated with 1 st dose, inside risk window	107,846	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	106,869	8	29.48	1.27	0.41–3.87	0.679	1.20	0.33–4.31	0.778
		Vaccinated with 2 nd dose, inside risk window	92,518	< 5	42.31	1.82	0.43–7.60	0.414	1.42	0.28–7.17	0.668
		Vaccinated with 2 nd dose, outside risk window	92,440	13	18.85	0.81	0.29–2.27	0.687	1.16	0.32–4.23	0.818
Encephalomyelitis and meningitis	28 days	<i>Overall</i>	121,166	< 5	1.50						
		Unvaccinated (ref.)	121,097	< 5	4.66	1			1		
		Vaccinated with 1 st dose, inside risk window	107,834	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	106,858	< 5	3.69	0.79	0.05–12.64	0.868	0.60	0.04–10.25	0.726
		Vaccinated with 2 nd dose, inside risk window	92,508	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,431	0	0.00	ND	ND	ND	ND	ND	ND
Epilepsy and convulsions	28 days	<i>Overall</i>	119,958	165	125.48						

		Unvaccinated (ref.)	119,891	26	122.46	1			1		
		Vaccinated with 1 st dose, inside risk window	106,752	6	73.40	0.60	0.25–1.46	0.258	0.62	0.24–1.61	0.326
		Vaccinated with 1 st dose, outside risk window	105,783	34	126.69	1.03	0.62–1.72	0.896	0.92	0.53–1.60	0.766
		Vaccinated with 2 nd dose, inside risk window	91,573	15	213.77	1.75	0.92–3.30	0.086	1.36	0.68–2.73	0.383
		Vaccinated with 2 nd dose, outside risk window	91,482	84	123.11	1.01	0.65–1.56	0.981	1.00	0.60–1.67	0.997
Facial nerve palsy	28 days	<i>Overall</i>	121,078	28	21.09						
		Unvaccinated (ref.)	121,009	5	23.31	1			1		
		Vaccinated with 1 st dose, inside risk window	107,751	< 5	12.12	0.52	0.06–4.45	0.550	0.26	0.03–2.29	0.225
		Vaccinated with 1 st dose, outside risk window	106,775	6	22.14	0.95	0.29–3.11	0.932	1.86	0.39–8.79	0.432
		Vaccinated with 2 nd dose, inside risk window	92,437	< 5	28.23	1.21	0.23–6.24	0.819	2.07	0.28–15.52	0.480
		Vaccinated with 2 nd dose, outside risk window	92,357	14	20.32	0.87	0.31–2.42	0.792	3.15	0.62–16.12	0.168
Guillain-Barré syndrome	42 days	<i>Overall</i>	121,172	< 5	1.50						
		Unvaccinated (ref.)	121,103	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	107,839	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	105,669	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	92,512	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,387	< 5	3.06	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	<i>Overall</i>	121,166	6	4.51						
		Unvaccinated (ref.)	121,097	< 5	4.66	1			1		
		Vaccinated with 1 st dose, inside risk window	107,832	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	105,662	< 5	8.67	1.86	0.17–20.53	0.612	1.12	0.10–12.83	0.926
		Vaccinated with 2 nd dose, inside risk window	92,504	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,379	< 5	4.59	0.98	0.10–9.46	0.989	0.78	0.06–9.44	0.843
Herpes zoster	28 days	<i>Overall</i>	121,117	21	15.81						
		Unvaccinated (ref.)	121,048	< 5	13.98	1			1		
		Vaccinated with 1 st dose, inside risk window	107,792	< 5	12.12	0.87	0.09–8.34	0.901	2.72	0.14–52.29	0.507
		Vaccinated with 1 st dose, outside risk window	106,815	< 5	7.38	0.53	0.09–3.16	0.484	0.57	0.09–3.47	0.542
		Vaccinated with 2 nd dose, inside risk window	92,476	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,398	15	21.76	1.56	0.45–5.38	0.484	0.68	0.19–2.41	0.545
Idiopathic thrombocytopenic purpura	28 days	<i>Overall</i>	121,150	< 5	2.26						
		Unvaccinated (ref.)	121,081	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	107,824	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	106,848	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	92,501	< 5	14.11	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,422	< 5	2.90	ND	ND	ND	ND	ND	ND
Lymphadenopathy	14 days	<i>Overall</i>	120,635	< 181	135.37						
		Unvaccinated (ref.)	120,566	26	121.68	1			1		
		Vaccinated with 1 st dose, inside risk window	107,344	< 5	72.92	0.60	0.18–1.98	0.401	0.70	0.20–2.50	0.587
		Vaccinated with 1 st dose, outside risk window	107,330	49	157.61	1.30	0.81–2.08	0.286	1.16	0.71–1.91	0.548
		Vaccinated with 2 nd dose, inside risk window	92,070	10	283.42	2.33	1.12–4.83	0.023	1.90	0.87–4.13	0.105
		Vaccinated with 2 nd dose, outside risk window	92,026	91	126.16	1.04	0.67–1.60	0.871	0.95	0.58–1.54	0.825
Multisystem inflammatory syndrome in children	42 days	<i>Overall</i>	121,176	8	6.02						
		Unvaccinated (ref.)	121,107	< 5	4.66	1			1		
		Vaccinated with 1 st dose, inside risk window	107,843	< 5	24.33	5.22	0.54–50.23	0.152	5.99	0.48–75.25	0.166
		Vaccinated with 1 st dose, outside risk window	105,670	< 5	4.34	0.93	0.06–14.89	0.960	0.74	0.05–12.22	0.836
		Vaccinated with 2 nd dose, inside risk window	92,516	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,391	< 5	4.58	0.98	0.10–9.47	0.989	0.95	0.08–12.00	0.968
Myocarditis and pericarditis	28 days	<i>Overall</i>	121,169	18	13.54						
		Unvaccinated (ref.)	121,100	< 5	9.32	1			1		
		Vaccinated with 1 st dose, inside risk window	107,839	< 5	12.11	1.30	0.12–14.33	0.831	1.54	0.11–20.77	0.746
		Vaccinated with 1 st dose, outside risk window	106,861	7	25.80	2.77	0.58–13.33	0.204	2.15	0.41–11.17	0.362

		Vaccinated with 2 nd dose, inside risk window	92,509	< 5	14.11	1.51	0.14–16.69	0.735	1.00	0.08–12.12	1.000
		Vaccinated with 2 nd dose, outside risk window	92,430	7	10.15	1.09	0.23–5.24	0.915	1.43	0.25–8.33	0.688
Venous thromboembolic events	28 days	<i>Overall</i>	121,147	27	20.32						
		Unvaccinated (ref.)	121,078	< 5	13.98	1			1		
		Vaccinated with 1 st dose, inside risk window	107,816	< 5	24.23	1.73	0.29–10.37	0.547	1.39	0.19–10.44	0.748
		Vaccinated with 1 st dose, outside risk window	106,837	5	18.43	1.32	0.32–5.52	0.705	1.51	0.31–7.41	0.609
		Vaccinated with 2 nd dose, inside risk window	92,488	< 5	14.11	1.01	0.10–9.70	0.994	1.31	0.11–15.54	0.829
		Vaccinated with 2 nd dose, outside risk window	92,409	16	23.21	1.66	0.48–5.70	0.421	1.36	0.31–5.94	0.679

Abbreviations: CI – confidence interval; IRR – incidence rate ratio; mRNA – messenger RNA; ND – not determined

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 4: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 121,584 adolescents in Norway aged 18–19 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination¹ of their age group until the outcome in question, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by “< 5”. As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of subjects	Number of events	Incidence rate ²	Crude analysis			Adjusted analysis ³		
						IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	<i>Overall</i>	120,562	349	250.73						
		Unvaccinated (ref.)	120,558	118	267.23	1			1		
		Vaccinated with 1 st dose, inside risk window	110,711	11	259.25	0.97	0.52–1.80	0.923	0.94	0.49–1.81	0.859
		Vaccinated with 1 st dose, outside risk window	110,671	47	273.35	1.02	0.73–1.43	0.895	1.09	0.72–1.64	0.696
		Vaccinated with 2 nd dose, inside risk window	104,941	9	223.78	0.84	0.43–1.65	0.608	0.83	0.40–1.71	0.607
		Vaccinated with 2 nd dose, outside risk window	104,910	164	235.70	0.88	0.70–1.12	0.298	1.02	0.71–1.46	0.929
Anaphylactic reaction	2 days	<i>Overall</i>	121,518	< 25	14.94						
		Unvaccinated (ref.)	121,514	5	11.23	1			1		
		Vaccinated with 1 st dose, inside risk window	111,693	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	111,690	8	38.05	3.39	1.11–10.36	0.032	8.49	1.91–37.66	0.005
		Vaccinated with 2 nd dose, inside risk window	105,912	< 5	172.43	15.36	1.79–131.46	0.013	38.78	3.46–434.39	0.003
		Vaccinated with 2 nd dose, outside risk window	105,909	7	9.49	0.84	0.27–2.66	0.774	2.10	0.37–12.07	0.406
Arrhythmia	28 days	<i>Overall</i>	121,337	< 57	38.49						
		Unvaccinated (ref.)	121,333	19	42.73	1			1		
		Vaccinated with 1 st dose, inside risk window	111,517	< 5	23.55	0.55	0.13–2.37	0.422	0.52	0.11–2.50	0.418
		Vaccinated with 1 st dose, outside risk window	101,548	8	61.02	1.43	0.63–3.26	0.398	1.06	0.42–2.66	0.907
		Vaccinated with 2 nd dose, inside risk window	105,749	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,684	25	37.80	0.88	0.49–1.61	0.687	0.58	0.27–1.26	0.169
Arthropathy	42 days	<i>Overall</i>	121,569	0	0.00						
		Unvaccinated (ref.)	121,565	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	111,743	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	67,275	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,968	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,857	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	<i>Overall</i>	121,533	6	4.27						
		Unvaccinated (ref.)	121,529	< 5	8.98	1			1		
		Vaccinated with 1 st dose, inside risk window	111,706	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	101,722	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,931	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,866	< 5	3.02	0.34	0.06–1.84	0.208	1.06	0.06–19.60	0.971
Death	28 days	<i>Overall</i>	121,569	48	34.14						
		Unvaccinated (ref.)	121,565	18	40.41	1			1		
		Vaccinated with 1 st dose, inside risk window	111,743	6	70.52	1.75	0.69–4.40	0.237	1.53	0.52–4.50	0.439
		Vaccinated with 1 st dose, outside risk window	101,754	< 5	22.84	0.57	0.17–1.92	0.360	0.70	0.18–2.73	0.610
		Vaccinated with 2 nd dose, inside risk window	105,968	< 5	24.63	0.61	0.14–2.63	0.507	0.59	0.12–2.92	0.521
		Vaccinated with 2 nd dose, outside risk window	105,903	19	28.67	0.71	0.37–1.35	0.297	1.30	0.46–3.66	0.623
Encephalomyelitis and meningitis	28 days	<i>Overall</i>	121,551	7	4.98						
		Unvaccinated (ref.)	121,547	< 5	2.25	1			1		
		Vaccinated with 1 st dose, inside risk window	111,727	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	101,739	< 5	7.61	3.39	0.21–54.23	0.388	1.43	0.09–22.99	0.799
		Vaccinated with 2 nd dose, inside risk window	105,952	< 5	12.32	5.48	0.34–87.69	0.229	4.67	0.22–100.73	0.325

		Vaccinated with 2 nd dose, outside risk window	105,886	< 5	6.04	2.69	0.30–24.06	0.376	0.80	0.09–7.48	0.846
Epilepsy and convulsions	28 days	<i>Overall</i>	120,364	155	111.40						
		Unvaccinated (ref.)	120,360	47	106.53	1			1		
		Vaccinated with 1 st dose, inside risk window	110,582	5	59.38	0.56	0.22–1.40	0.214	0.73	0.27–1.98	0.538
		Vaccinated with 1 st dose, outside risk window	100,711	21	161.49	1.52	0.91–2.54	0.113	1.85	0.97–3.54	0.064
		Vaccinated with 2 nd dose, inside risk window	104,852	14	174.23	1.64	0.90–2.97	0.106	2.20	1.05–4.61	0.036
		Vaccinated with 2 nd dose, outside risk window	104,776	68	103.72	0.97	0.67–1.41	0.888	1.08	0.60–1.93	0.806
Facial nerve palsy	28 days	<i>Overall</i>	121,480	< 30	18.51						
		Unvaccinated (ref.)	121,476	11	24.71	1			1		
		Vaccinated with 1 st dose, inside risk window	111,654	< 5	11.76	0.48	0.06–3.69	0.478	0.70	0.07–6.96	0.762
		Vaccinated with 1 st dose, outside risk window	101,671	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,888	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,823	14	21.14	0.86	0.39–1.88	0.699	0.48	0.16–1.40	0.180
Guillain-Barré syndrome	42 days	<i>Overall</i>	121,566	< 5	0.71						
		Unvaccinated (ref.)	121,562	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	111,740	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	67,273	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,965	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,854	< 5	1.61	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	<i>Overall</i>	121,555	< 5	1.42						
		Unvaccinated (ref.)	121,551	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	111,731	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	67,270	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,956	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,845	< 5	3.21	ND	ND	ND	ND	ND	ND
Herpes zoster	28 days	<i>Overall</i>	121,508	19	13.52						
		Unvaccinated (ref.)	121,504	5	11.23	1			1		
		Vaccinated with 1 st dose, inside risk window	111,680	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	101,697	< 5	22.85	2.04	0.49–8.52	0.330	1.70	0.31–9.34	0.544
		Vaccinated with 2 nd dose, inside risk window	105,908	< 5	12.32	1.10	0.13–9.40	0.932	1.09	0.10–12.23	0.942
		Vaccinated with 2 nd dose, outside risk window	105,842	10	15.10	1.35	0.46–3.94	0.588	0.88	0.19–3.98	0.868
Idiopathic thrombocytopenic purpura	28 days	<i>Overall</i>	121,538	< 10	5.69						
		Unvaccinated (ref.)	121,534	< 5	6.74	1			1		
		Vaccinated with 1 st dose, inside risk window	111,711	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	101,728	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,936	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,872	5	7.55	1.12	0.27–4.69	0.877	2.45	0.39–15.45	0.340
Lymphadenopathy	14 days	<i>Overall</i>	120,995	182	130.15						
		Unvaccinated (ref.)	120,991	52	117.29	1			1		
		Vaccinated with 1 st dose, inside risk window	111,165	6	140.83	1.20	0.52–2.80	0.671	1.30	0.53–3.16	0.568
		Vaccinated with 1 st dose, outside risk window	111,130	15	86.87	0.74	0.42–1.32	0.306	0.84	0.43–1.64	0.610
		Vaccinated with 2 nd dose, inside risk window	105,405	10	247.56	2.11	1.07–4.15	0.031	2.37	1.09–5.15	0.030
		Vaccinated with 2 nd dose, outside risk window	105,373	99	141.57	1.21	0.86–1.69	0.272	1.30	0.77–2.20	0.330
Multisystem inflammatory syndrome in children	42 days	<i>Overall</i>	121,563	< 5	0.71						
		Unvaccinated (ref.)	121,559	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	111,737	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	67,272	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,964	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,853	< 5	1.61	ND	ND	ND	ND	ND	ND
Myocarditis and pericarditis	28 days	<i>Overall</i>	121,531	< 41	27.04						
		Unvaccinated (ref.)	121,527	8	17.96	1			1		

		Vaccinated with 1 st dose, inside risk window	111,700	< 5	23.51	1.31	0.28–6.16	0.733	1.87	0.31–11.29	0.493
		Vaccinated with 1 st dose, outside risk window	101,714	5	38.10	2.12	0.69–6.48	0.187	3.91	0.81–18.77	0.089
		Vaccinated with 2 nd dose, inside risk window	105,926	9	110.87	6.17	2.38–16.00	< 0.001	10.25	2.36–44.47	0.002
		Vaccinated with 2 nd dose, outside risk window	105,852	14	21.14	1.18	0.49–2.81	0.713	2.84	0.61–13.15	0.182
Venous thromboembolic events	28 days	<i>Overall</i>	121,513	26	18.50						
		Unvaccinated (ref.)	121,509	6	13.47	1			1		
		Vaccinated with 1 st dose, inside risk window	111,684	< 5	35.28	2.62	0.65–10.47	0.173	5.07	0.96–26.81	0.056
		Vaccinated with 1 st dose, outside risk window	101,699	< 5	15.23	1.13	0.23–5.60	0.881	2.39	0.31–18.51	0.403
		Vaccinated with 2 nd dose, inside risk window	105,907	< 5	24.64	1.83	0.37–9.06	0.460	3.99	0.52–30.36	0.181
		Vaccinated with 2 nd dose, outside risk window	105,840	13	19.63	1.46	0.55–3.83	0.446	2.59	0.43–15.41	0.296

Abbreviations: CI – confidence interval; IRR – incidence rate ratio; mRNA – messenger RNA; ND – not determined

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 5: Adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on self-controlled case series (SCCS) analysis of adolescents in Norway aged 12–19 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up.

Outcome	Risk window	Vaccination status	Number of events	Adjusted analysis ¹		
				IRR	95% CI	P value
Acute appendicitis	14 days	<i>Total</i>	1,185			
		Unvaccinated (ref.)	267	1		
		Vaccinated with 1 st dose, inside risk window	36	1.05	0.72–1.54	0.79
		Vaccinated with 1 st dose, outside risk window	495	1.15	0.90–1.45	0.26
		Vaccinated with 2 nd dose, inside risk window	21	1.02	0.64–1.63	0.94
		Vaccinated with 2 nd dose, outside risk window	366	0.97	0.78–1.22	0.81
Anaphylactic reaction	2 days	<i>Total</i>	< 61			
		Unvaccinated (ref.)	12	1		
		Vaccinated with 1 st dose, inside risk window	< 5	4.92	0.59–41.11	0.14
		Vaccinated with 1 st dose, outside risk window	26	2.02	0.74–5.49	0.17
		Vaccinated with 2 nd dose, inside risk window	< 5	2.02	0.89–64.17	0.06
		Vaccinated with 2 nd dose, outside risk window	16	0.77	0.29–2.03	0.60
Arrhythmia	28 days	<i>Total</i>	135			
		Unvaccinated (ref.)	39	1		
		Vaccinated with 1 st dose, inside risk window	< 5	0.48	0.16–1.41	0.18
		Vaccinated with 1 st dose, outside risk window	43	1.01	0.53–1.91	0.99
		Vaccinated with 2 nd dose, inside risk window	< 5	0.19	0.03–1.45	0.11
		Vaccinated with 2 nd dose, outside risk window	48	1.30	0.71–2.39	0.39
Arthropathy	42 days	<i>Total</i>	0			
		Unvaccinated (ref.)	0	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	0	ND	ND	ND
Cerebrovascular events	28 days	<i>Total</i>	< 33			
		Unvaccinated (ref.)	10	1		
		Vaccinated with 1 st dose, inside risk window	< 5	1.22	0.26–5.72	0.80

		Vaccinated with 1 st dose, outside risk window	12	0.80	0.22–2.92	0.74
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	6	0.44	0.11–1.75	0.24
Death	28 days	<i>Total</i>				
		Unvaccinated (ref.)		1		
		Vaccinated with 1 st dose, inside risk window		ND	ND	ND
		Vaccinated with 1 st dose, outside risk window		ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window		ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window		ND	ND	ND
Encephalomyelitis and meningitis	28 days	<i>Total</i>	14			
		Unvaccinated (ref.)	< 5	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	5	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	< 5	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	< 5	ND	ND	ND
Epilepsy and convulsions	28 days	<i>Total</i>	617			
		Unvaccinated (ref.)	165	1		
		Vaccinated with 1 st dose, inside risk window	29	0.95	0.59–1.52	0.83
		Vaccinated with 1 st dose, outside risk window	225	1.08	0.76–1.56	0.66
		Vaccinated with 2 nd dose, inside risk window	30	1.59	0.99–2.55	0.05
		Vaccinated with 2 nd dose, outside risk window	168	1.08	0.77–1.52	0.66
Facial nerve palsy	28 days	<i>Total</i>	91			
		Unvaccinated (ref.)	34	1		
		Vaccinated with 1 st dose, inside risk window	< 5	0.89	0.27–2.96	0.85
		Vaccinated with 1 st dose, outside risk window	20	0.96	0.37–2.48	0.93
		Vaccinated with 2 nd dose, inside risk window	< 5	0.64	0.13–3.04	0.57
		Vaccinated with 2 nd dose, outside risk window	31	1.11	0.49–2.52	0.81
Guillain-Barré syndrome	42 days	<i>Total</i>	6			
		Unvaccinated (ref.)	0	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	< 5	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	< 5	ND	ND	ND

Henoch-Schönlein purpura	42 days	<i>Total</i>	< 17			
		Unvaccinated (ref.)	< 5	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	7	0.63	0.07–5.44	0.67
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	5	1.48	0.12–18.91	0.76
Herpes zoster	28 days	<i>Total</i>	80			
		Unvaccinated (ref.)	18	1		
		Vaccinated with 1 st dose, inside risk window	< 5	1.56	0.25–9.67	0.63
		Vaccinated with 1 st dose, outside risk window	29	2.26	0.56–9.19	0.25
		Vaccinated with 2 nd dose, inside risk window	< 5	1.65	0.16–16.80	0.67
		Vaccinated with 2 nd dose, outside risk window	30	4.12	1.10–15.4	0.04
Idiopathic thrombocytopenic purpura	28 days	<i>Total</i>	24			
		Unvaccinated (ref.)	6	1		
		Vaccinated with 1 st dose, inside risk window	< 5	0.75	0.18–10.66	0.75
		Vaccinated with 1 st dose, outside risk window	8	0.89	0.12–6.78	0.91
		Vaccinated with 2 nd dose, inside risk window	< 5	1.21	0.10–13.89	0.88
		Vaccinated with 2 nd dose, outside risk window	7	1.09	0.19–6.41	0.92
Lymphadenopathy	14 days	<i>Total</i>	651			
		Unvaccinated (ref.)	152	1		
		Vaccinated with 1 st dose, inside risk window	15	0.79	0.45–1.40	0.43
		Vaccinated with 1 st dose, outside risk window	249	1.00	0.73–1.38	0.98
		Vaccinated with 2 nd dose, inside risk window	22	2.04	1.24–3.35	0.01
		Vaccinated with 2 nd dose, outside risk window	213	1.08	0.80–1.47	0.61
Multisystem inflammatory syndrome in children	42 days	<i>Total</i>	21			
		Unvaccinated (ref.)	6	1		
		Vaccinated with 1 st dose, inside risk window	< 5	1.14	0.17–7.52	0.89
		Vaccinated with 1 st dose, outside risk window	8	0.47	0.09–2.62	0.39
		Vaccinated with 2 nd dose, inside risk window	0	NA	NA	NA
		Vaccinated with 2 nd dose, outside risk window	< 5	1.33	0.11–16.65	0.82
Myocarditis and pericarditis	28 days	<i>Total</i>	< 68			
		Unvaccinated (ref.)	13	1		
		Vaccinated with 1 st dose, inside risk window	< 5	1.20	0.30–4.84	0.80

		Vaccinated with 1 st dose, outside risk window	17	1.60	0.53–4.84	0.40
		Vaccinated with 2 nd dose, inside risk window	11	5.88	2.11–16.40	<0.001
		Vaccinated with 2 nd dose, outside risk window	22	1.14	0.45–2.93	0.78
Venous thromboembolic events	28 days	<i>Total</i>	< 71			
		Unvaccinated (ref.)	11	1		
		Vaccinated with 1 st dose, inside risk window	5	1.05	0.35–3.16	0.93
		Vaccinated with 1 st dose, outside risk window	20	1.04	0.42–2.62	0.93
		Vaccinated with 2 nd dose, inside risk window	< 5	0.81	0.22–3.02	0.75
		Vaccinated with 2 nd dose, outside risk window	30	0.98	0.45–2.14	0.95

¹Adjustment for seasonality, defined as quarterly time periods (January–March, April–June, July–September, and October–December)